Author

C. A. Berdan

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:metabolism & bioenergetics· 1 Assay:metabolomics· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

D. K. Nomura· 2 shared A. Stahl· 1 shared C. R. Altobelli· 1 shared D. F. Covey· 1 shared D. Nomura· 1 shared D. S. Ory· 1 shared E. Weiss· 1 shared H. S. Lehtola· 1 shared

Activity by Year

2019-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

D. K. Nomura

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

4 β-hydroxycholesterol is a pro-lipogenic factor that promotes SREBP1c expression and activity through Liver X-receptor.

O. Moldavski, P.-J. H. Zushin, C. A. Berdan, R. J. van Eijkeren, X. Jiang, M. Qian, D. S. Ory, D. F. Covey, D. Nomura, A. Stahl, E. Weiss, R. Zoncu

This study identifies 4β-hydroxycholesterol as a pro-lipogenic factor that activates SREBP1c via LXR to promote de novo lipogenesis.

bioRxiv · Aug 20, 2020Biochemistry

Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells

C. A. Berdan, R. Ho, H. S. Lehtola, M. To, X. Hu, T. R. Huffman, Y. Petri, C. R. Altobelli, S. G. Demeulenaere, J. A. Olzmann, T. J. Maimone, D. K. Nomura

This study identifies parthenolide's covalent targeting of FAK1 in breast cancer cells, showing inhibition of FAK1-dependent pathways and cancer cell proliferation.

bioRxiv · Feb 15, 2019Cancer Biology

A metabolic dependency for host isoprenoids in the obligate intracellular pathogen Rickettsia parkeri underlies a sensitivity for the statin class of host-targeted therapeutics

V. Ahyong, C. A. Berdan, D. K. Nomura, M. D. Welch

This study identifies a metabolic dependency of Rickettsia parkeri on host isoprenoids, showing that statin drugs inhibit bacterial growth by disrupting cell wall synthesis.

bioRxiv · Jan 23, 2019Microbiology